• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Mural Oncology Announces Final Cash Consideration Payable on Closing of Acquisition by XOMA Royalty

    11/26/25 9:00:00 AM ET
    $MURA
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MURA alert in real time by email

    WALTHAM, Mass. and DUBLIN, Ireland, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc (NASDAQ:MURA) ("Mural") announces that, in accordance with the terms of the transaction agreement between XOMA Royalty Corporation (NASDAQ:XOMA) ("XOMA Royalty"), XRA 5 Corp. ("Sub") and Mural announced on August 20, 2025 (the "Transaction Agreement"), the Additional Price Per Share (as defined in the Transaction Agreement) has been finally determined in accordance with Clause 2.4 of the Transaction Agreement as $0.000. As a result, the total cash consideration payable to Mural shareholders on closing of the Acquisition (as defined below) will be $2.035 in cash per share.

    As previously announced on August 20, 2025, XOMA Royalty, Sub and Mural entered into the Transaction Agreement pursuant to which Sub, a wholly-owned subsidiary of XOMA Royalty, has agreed to acquire the entire issued and to be issued share capital of Mural (the "Acquisition") pursuant to an Irish High Court sanctioned "scheme of arrangement" under Chapter 1 of Part 9 of the Irish Companies Act of 2014 (the "Scheme").

    The Acquisition is expected to close in early December 2025, subject to the satisfaction of the outstanding closing conditions and the sanction of the Scheme by the Irish High Court.

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION

    FOR IMMEDIATE RELEASE

    Enquiries

    Mural Oncology plc

    [email protected]

    Lucid Capital Markets, LLC (Financial Adviser to Mural)

    570 Lexington Ave, 40th Floor

    New York, NY 10022

    Cautionary Note Regarding Forward-Looking Statements

    Statements contained in this announcement regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 with respect to Mural, XOMA Royalty or Sub. Forward-looking statements are intended to be identified by words such as "anticipate", "target", "expect", "estimate", "intend", "plan", "believe", "will", "may", "would", "could" or "should" or other words of similar meaning or the negative thereof. Forward-looking statements include but are not limited to statements regarding Mural, XOMA Royalty and Sub's intention to consummate the Acquisition and the expected timing of the closing of the Acquisition.

    These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results to be materially different from those expressed or implied by such forward-looking statements. Risks and uncertainties that may cause actual results to differ from expectations include: uncertainties as to the possibility that closing conditions for the Acquisition may not be satisfied or waived, including the failure to receive sanction of the Scheme by the Irish High Court; the other risks and uncertainties pertaining to Mural's business, including those described in Mural's most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission ("SEC") and the definitive proxy statement filed with the SEC on September 23, 2025, as well as Mural's subsequent filings with the SEC; and other potential risks and uncertainties related to XOMA Royalty, including those described in more detail in XOMA Royalty's most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and its other filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date when made. All subsequent oral or written forward-looking statements attributable to Mural, XOMA Royalty or Sub or any persons acting on their behalf are expressly qualified in their entirety by the cautionary statement above. None of Mural, XOMA Royalty or Sub undertake any obligation to update or revise the forward-looking statements contained in this announcement, whether as a result of new information, future events or otherwise, except to the extent legally required.

    Statement Required by the Irish Takeover Rules 

    The directors of Mural accept responsibility for the information contained in this announcement. To the best of the knowledge and belief of the directors of Mural (who have taken all reasonable care to ensure such is the case), the information contained in this announcement is in accordance with the facts and does not omit anything likely to affect the import of such information.

    Disclosure Requirements of the Irish Takeover Rules

    Under Rule 8.3(b) of the Irish Takeover Rules, any person who is, or becomes, "interested" (directly or indirectly) in 1% or more of any class of "relevant securities" of Mural must disclose all "dealings" in such "relevant securities" during the "offer period". The disclosure of a "dealing" in "relevant securities" by a person to whom Rule 8.3(b) applies must be made by no later than 3:30pm (U.S. Eastern Time) on the "business day" following the date of the relevant "dealing". A dealing disclosure must contain the details specified in Rule 8.6(b) of the Irish Takeover Rules, including details of the dealing concerned and of the person's interests and short positions in any "relevant securities" of Mural.

    All "dealings" in "relevant securities" of Mural by a bidder, or by any party acting in concert with a bidder, must also be disclosed by no later than 12:00 noon (U.S. Eastern Time) on the "business day" following the date of the relevant "dealing".

    If two or more persons co-operate on the basis of an agreement, either express or tacit, either oral or written, to acquire an "interest" in "relevant securities" of Mural, they will be deemed to be a single person for the purpose of Rule 8.3(a) and (b) of the Irish Takeover Rules.

    A disclosure table, giving details of the companies in whose "relevant securities" dealing disclosures should be made, can be found on the Irish Takeover Panel's website at www.irishtakeoverpanel.ie.

    "Interests in securities" arise, in summary, when a person has long economic exposure, whether conditional or absolute, to changes in the price of securities. In particular, a person will be treated as having an "interest" by virtue of the ownership or control of securities, or by virtue of any option in respect of, or derivative referenced to, securities.

    Terms in quotation marks in this section are defined in the Irish Takeover Rules, which can also be found on the Irish Takeover Panel's website.

    If you are in any doubt as to whether or not you are required to disclose a "dealing" under Rule 8, please consult the Irish Takeover Panel's website at www.irishtakeoverpanel.ie or contact the Irish Takeover Panel on telephone number +353 1 678 9020.

    General

    The release, publication or distribution of this announcement in or into certain jurisdictions may be restricted by the laws of those jurisdictions. Accordingly, copies of this announcement and all other documents relating to the Acquisition are not being, and must not be, released, published, mailed or otherwise forwarded, distributed or sent in, into or from any such restricted jurisdictions. Persons receiving such documents (including, without limitation, nominees, trustees and custodians) should observe these restrictions. Failure to do so may constitute a violation of the securities laws of any such jurisdiction. To the fullest extent permitted by applicable law, each of Mural, XOMA Royalty and Sub disclaims any responsibility or liability for the violations of any such restrictions by any person.

    Publication on a Website

    In accordance with Rule 26.1 of the Irish Takeover Rules, a copy of this announcement will be available on Mural's website at https://ir.muraloncology.com/ by no later than 12:00 noon (U.S. Eastern Time) on the business day following publication of this announcement. Neither the content of the website referred to in this announcement nor the content of any other websites accessible from hyperlinks on such website is incorporated into, or forms part of, this announcement.



    Primary Logo

    Get the next $MURA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MURA
    $XOMA

    CompanyDatePrice TargetRatingAnalyst
    XOMA Royalty Corporation
    $XOMA
    4/17/2025$35.00Buy
    The Benchmark Company
    Mural Oncology plc
    $MURA
    3/25/2025Overweight → Equal-Weight
    Morgan Stanley
    Mural Oncology plc
    $MURA
    3/25/2025$18.00Strong Buy → Outperform
    Raymond James
    Mural Oncology plc
    $MURA
    6/28/2024$15.00Buy
    Rodman & Renshaw
    XOMA Royalty Corporation
    $XOMA
    4/29/2024$40.00Outperform
    Leerink Partners
    Mural Oncology plc
    $MURA
    4/4/2024$13.00Overweight
    Morgan Stanley
    XOMA Royalty Corporation
    $XOMA
    10/8/2021$56.00 → $69.00Buy
    HC Wainwright & Co.
    XOMA Royalty Corporation
    $XOMA
    9/9/2021$60.00 → $56.00Buy
    Aegis Capital
    More analyst ratings

    $MURA
    $XOMA
    SEC Filings

    View All

    XOMA Royalty Corporation filed SEC Form 8-K: Financial Statements and Exhibits

    8-K - XOMA Royalty Corp (0000791908) (Filer)

    11/21/25 8:03:29 AM ET
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Mural Oncology plc

    SCHEDULE 13G/A - Mural Oncology plc (0001971543) (Subject)

    11/13/25 7:39:08 PM ET
    $MURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by XOMA Royalty Corporation

    10-Q - XOMA Royalty Corp (0000791908) (Filer)

    11/12/25 7:46:01 AM ET
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MURA
    $XOMA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Goodman Vicki L sold $10,475 worth of Ordinary Shares (5,036 units at $2.08), decreasing direct ownership by 6% to 84,727 units (SEC Form 4)

    4 - Mural Oncology plc (0001971543) (Issuer)

    11/10/25 6:30:03 PM ET
    $MURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Cutler Adam D. sold $14,939 worth of Ordinary Shares (7,148 units at $2.09), decreasing direct ownership by 7% to 99,290 units (SEC Form 4)

    4 - Mural Oncology plc (0001971543) (Issuer)

    11/10/25 6:30:04 PM ET
    $MURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Investment Officer Sitko Bradley converted options into 6,712 shares, increasing direct ownership by 51% to 19,822 units (SEC Form 4)

    4 - XOMA Royalty Corp (0000791908) (Issuer)

    9/23/25 5:32:53 PM ET
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MURA
    $XOMA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Investment Officer Sitko Bradley bought $50,780 worth of Depositary Shares - 8.375% Series B Cumulative Stock (2,000 units at $25.39), increasing direct ownership by 40% to 7,045 units (SEC Form 4)

    4 - XOMA Royalty Corp (0000791908) (Issuer)

    7/2/25 4:30:26 PM ET
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Investment Officer Sitko Bradley bought $49,400 worth of Depositary Shares - 8.375% Series B Cumulative Stock (2,000 units at $24.70), increasing direct ownership by 66% to 5,045 units (SEC Form 4)

    4 - XOMA Royalty Corp (0000791908) (Issuer)

    4/9/25 4:44:30 PM ET
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Limber Joseph M bought $504,504 worth of Depositary Shares - 8.375% Series B Cumulative Stock (20,000 units at $25.23) and bought $255,640 worth of 8.625% Series A Cumulative Perpetual Preferred Stock (10,000 units at $25.56) (SEC Form 4)

    4 - XOMA Royalty Corp (0000791908) (Issuer)

    4/7/25 4:39:59 PM ET
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MURA
    $XOMA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Mural Oncology Announces Final Cash Consideration Payable on Closing of Acquisition by XOMA Royalty

    WALTHAM, Mass. and DUBLIN, Ireland, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc (NASDAQ:MURA) ("Mural") announces that, in accordance with the terms of the transaction agreement between XOMA Royalty Corporation (NASDAQ:XOMA) ("XOMA Royalty"), XRA 5 Corp. ("Sub") and Mural announced on August 20, 2025 (the "Transaction Agreement"), the Additional Price Per Share (as defined in the Transaction Agreement) has been finally determined in accordance with Clause 2.4 of the Transaction Agreement as $0.000. As a result, the total cash consideration payable to Mural shareholders on closing of the Acquisition (as defined below) will be $2.035 in cash per share. As previously announced on Au

    11/26/25 9:00:00 AM ET
    $MURA
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    XOMA Royalty Announces Closing of Transactions to Acquire LAVA Therapeutics N.V.

    EMERYVILLE, Calif., Nov. 21, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation ("XOMA Royalty") (NASDAQ:XOMA) today announced it has successfully completed its previously announced acquisition of all the outstanding common shares of LAVA Therapeutics N.V. ("LAVA") (NASDAQ:LVTX) with a nominal value of €0.12 per share ("Shares").  LAVA shareholders received $1.04 in cash per Share and a non-transferrable contingent value right ("CVR") per Share representing the right to receive certain cash payments, including (A) the right to receive, among other things, 75% of any net proceeds related to LAVA's two partnered assets plus 75% of any net proceeds from any out license or sale of LAVA's unpart

    11/21/25 7:45:00 AM ET
    $LVTX
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LAVA Therapeutics N.V. Shareholders are Reminded to Tender Shares for XOMA Royalty Transaction Before November 12, 2025 Deadline

    UTRECHT, The Netherlands and PHILADELPHIA, Nov. 10, 2025 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. ("LAVA") (NASDAQ:LVTX) today announced a reminder to LAVA shareholders related to the proposed transaction with XOMA Royalty Corporation ("XOMA") (NASDAQ:XOMA). On August 4, 2025, XOMA and LAVA announced they had entered into a share purchase agreement. More recently, on October 17, 2025, XOMA announced it had extended its offer (the "Offer") to purchase all outstanding common shares of LAVA until one minute after 11:59 p.m., Eastern time, on November 12, 2025 (the "Expiration Time"). LAVA would like to remind LAVA shareholders to tender their shares prior to the Expiration Time. If less t

    11/10/25 4:09:25 PM ET
    $LVTX
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MURA
    $XOMA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    The Benchmark Company initiated coverage on XOMA Royalty Corporation with a new price target

    The Benchmark Company initiated coverage of XOMA Royalty Corporation with a rating of Buy and set a new price target of $35.00

    4/17/25 8:34:06 AM ET
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mural Oncology downgraded by Morgan Stanley

    Morgan Stanley downgraded Mural Oncology from Overweight to Equal-Weight

    3/25/25 12:58:54 PM ET
    $MURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mural Oncology downgraded by Raymond James with a new price target

    Raymond James downgraded Mural Oncology from Strong Buy to Outperform and set a new price target of $18.00

    3/25/25 11:43:59 AM ET
    $MURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MURA
    $XOMA
    Leadership Updates

    Live Leadership Updates

    View All

    Mural Oncology Announces Third Quarter 2024 Financial Results and Provides Update on Pipeline Progress

    Company remains on track in late-stage, potentially registrational trials of nemvaleukin alfa, with data readouts expected in late Q1/early Q2 2025 for platinum-resistant ovarian cancer and Q2 2025 for mucosal melanoma Candidate nominations for IL-18 and IL-12 programs expected in Q4 2024, and IND submission for Mural's IL-18 program planned for Q4 2025 Mural reiterates guidance on projected cash runway into Q4 2025 WALTHAM, Mass. and DUBLIN, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (NASDAQ:MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of can

    11/13/24 7:00:00 AM ET
    $MURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mural Oncology's First Virtual Investor Day to Highlight Late-Stage Clinical Progress

    Key data readouts for the company's late-stage, potentially registrational trials of nemvaleukin are expected in late Q1/early Q2 2025 for platinum-resistant ovarian cancer and Q2 2025 for mucosal melanoma Management team to provide additional information not previously disclosed related to nemvaleukin study design, statistical assumptions, and study execution Clinicians to discuss treatment landscape of platinum-resistant ovarian cancer and mucosal melanoma, two indications with limited treatment options and poor outcomes for patients IND submission for Mural's IL-18 program planned for Q4 2025 WALTHAM, Mass and DUBLIN, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (NASDAQ:MUR

    9/26/24 7:00:00 AM ET
    $MURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mural Oncology Strengthens Board of Directors with the Appointment of Sachiyo Minegishi

    WALTHAM, Mass and DUBLIN, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (NASDAQ:MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today announced the appointment of Sachiyo Minegishi to its board of directors, effective September 20. Ms. Minegishi will serve as Chair of the Audit Committee and will also be joining the company's Nominating and Corporate Governance Committee. "With over 20 years of industry experience, Sachiyo brings a successful record of helping companies navigate through important clinical, financial, and corporate mileston

    9/23/24 7:00:00 AM ET
    $MURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MURA
    $XOMA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Mural Oncology plc

    SC 13G/A - Mural Oncology plc (0001971543) (Subject)

    11/14/24 5:15:53 PM ET
    $MURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Mural Oncology plc

    SC 13G/A - Mural Oncology plc (0001971543) (Subject)

    11/12/24 3:52:44 PM ET
    $MURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Mural Oncology plc

    SC 13G/A - Mural Oncology plc (0001971543) (Subject)

    11/4/24 2:39:13 PM ET
    $MURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MURA
    $XOMA
    Financials

    Live finance-specific insights

    View All

    Mural Oncology Announces that Mural Shareholders Approve the Proposed Acquisition by XRA 5 Corp., a Wholly Owned Subsidiary of XOMA Royalty

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION  WALTHAM, Mass. and DUBLIN, Ireland, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc (NASDAQ:MURA) ("Mural") today announced that its shareholders have voted to approve the previously announced proposed acquisition of Mural by XRA 5 Corp. ("Sub"), a wholly owned subsidiary of XOMA Royalty Corporation (NASDAQ:XOMA) ("XOMA Royalty"). As described in more detail below, a majority in number of the shareholders of record present and voting, either in person or by proxy and more than 99 perc

    10/24/25 4:25:31 PM ET
    $MURA
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    XOMA Royalty and LAVA Therapeutics Announce Amendment to Purchase Agreement

    - Amendment includes finalized cash amount and updated CVR terms for tender offer - LAVA announces new date for extraordinary general meeting of shareholders EMERYVILLE, Calif. and UTRECHT, The Netherlands and PHILADELPHIA, Penn., Oct. 17, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation ("XOMA Royalty") (NASDAQ:XOMA) and LAVA Therapeutics N.V. ("LAVA") (NASDAQ:LVTX) today announced that they have reached an agreement to amend their previously announced definitive share purchase agreement (the "Purchase Agreement," and such amendment, the "Amendment").   Under the Amendment, LAVA shareholders who tender their shares will now receive (i) an initial cash amount per share of $1.04 (the "

    10/17/25 11:45:00 AM ET
    $LVTX
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    XOMA Royalty Extends Tender Offer to Acquire LAVA Therapeutics N.V.

    EMERYVILLE, Calif. and UTRECHT, The Netherlands and PHILADELPHIA, Oct. 02, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation ("XOMA Royalty") (NASDAQ:XOMA) and LAVA Therapeutics N.V. ("LAVA") (NASDAQ:LVTX) today announced the extension of the expiration of the tender offer to purchase all outstanding shares of common shares of LAVA, for (i) a cash amount to be determined in accordance with the Purchase Agreement, plus (ii) a non-transferable contingent value right ("CVR") per share representing the right to receive 75% of the net proceeds related to LAVA's two partnered assets and 75% of any net proceeds from any out license or sale of LAVA's unpartnered programs (the "Offer"). The Offer,

    10/2/25 4:43:26 PM ET
    $LVTX
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care